Logo image of SCPX

SCORPIUS HOLDINGS INC (SCPX) Stock Fundamental Analysis

NYSEARCA:SCPX - NYSE Arca - US42237K5083 - Common Stock - Currency: USD

0.068  -0.06 (-48.48%)

Fundamental Rating

2

SCPX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. SCPX may be in some trouble as it scores bad on both profitability and health. SCPX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCPX has reported negative net income.
In the past year SCPX has reported a negative cash flow from operations.
SCPX had negative earnings in each of the past 5 years.
SCPX had a negative operating cash flow in each of the past 5 years.
SCPX Yearly Net Income VS EBIT VS OCF VS FCFSCPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

SCPX has a worse Return On Assets (-72.96%) than 66.49% of its industry peers.
SCPX has a worse Return On Equity (-128.83%) than 60.32% of its industry peers.
Industry RankSector Rank
ROA -72.96%
ROE -128.83%
ROIC N/A
ROA(3y)-53.06%
ROA(5y)-51.43%
ROE(3y)-77.93%
ROE(5y)-80.68%
ROIC(3y)N/A
ROIC(5y)N/A
SCPX Yearly ROA, ROE, ROICSCPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

SCPX's Gross Margin of 68.54% is amongst the best of the industry. SCPX outperforms 80.60% of its industry peers.
SCPX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPX Yearly Profit, Operating, Gross MarginsSCPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

SCPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCPX has more shares outstanding than it did 1 year ago.
SCPX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SCPX is higher compared to a year ago.
SCPX Yearly Shares OutstandingSCPX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
SCPX Yearly Total Debt VS Total AssetsSCPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -9.40, we must say that SCPX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.40, SCPX is not doing good in the industry: 72.66% of the companies in the same industry are doing better.
SCPX has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.31, SCPX is not doing good in the industry: 71.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -9.4
ROIC/WACCN/A
WACC4.43%
SCPX Yearly LT Debt VS Equity VS FCFSCPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

SCPX has a Current Ratio of 0.38. This is a bad value and indicates that SCPX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of SCPX (0.38) is worse than 94.36% of its industry peers.
A Quick Ratio of 0.26 indicates that SCPX may have some problems paying its short term obligations.
SCPX has a worse Quick ratio (0.26) than 95.24% of its industry peers.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.26
SCPX Yearly Current Assets VS Current LiabilitesSCPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.42% over the past year.
Looking at the last year, SCPX shows a very strong growth in Revenue. The Revenue has grown by 947.53%.
The Revenue has been growing slightly by 3.85% on average over the past years.
EPS 1Y (TTM)20.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68%
Revenue 1Y (TTM)947.53%
Revenue growth 3Y33.35%
Revenue growth 5Y3.85%
Sales Q2Q%356.36%

3.2 Future

The Earnings Per Share is expected to grow by 41.10% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 80.70% on average over the next years. This is a very strong growth
EPS Next Y97.7%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year63.27%
Revenue Next 2Y80.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SCPX Yearly Revenue VS EstimatesSCPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
SCPX Yearly EPS VS EstimatesSCPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPX Price Earnings VS Forward Price EarningsSCPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPX Per share dataSCPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

SCPX's earnings are expected to grow with 41.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCORPIUS HOLDINGS INC

NYSEARCA:SCPX (4/21/2025, 8:04:00 PM)

0.068

-0.06 (-48.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)05-26 2025-05-26
Inst Owners0.19%
Inst Owner ChangeN/A
Ins Owners0.71%
Ins Owner Change0%
Market Cap331.16K
Analysts82.86
Price Target5.1 (7400%)
Short Float %7.53%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.01
P/tB 0.01
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-4.74
FCFYN/A
OCF(TTM)-4.61
OCFYN/A
SpS2
BVpS5.87
TBVpS5.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.96%
ROE -128.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.54%
FCFM N/A
ROA(3y)-53.06%
ROA(5y)-51.43%
ROE(3y)-77.93%
ROE(5y)-80.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.24%
Cap/Sales 6.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.26
Altman-Z -9.4
F-Score3
WACC4.43%
ROIC/WACCN/A
Cap/Depr(3y)326.96%
Cap/Depr(5y)240.26%
Cap/Sales(3y)144.6%
Cap/Sales(5y)90.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68%
EPS Next Y97.7%
EPS Next 2Y41.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)947.53%
Revenue growth 3Y33.35%
Revenue growth 5Y3.85%
Sales Q2Q%356.36%
Revenue Next Year63.27%
Revenue Next 2Y80.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.43%
OCF growth 3YN/A
OCF growth 5YN/A